Aardvark Therapeutics' (AARD) "Overweight" Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Aardvark Therapeutics (NASDAQ:AARD - Free Report) in a research report released on Tuesday morning,Benzinga reports. Cantor Fitzgerald currently has a $50.00 price target on the stock.

A number of other equities research analysts have also recently issued reports on the stock. Morgan Stanley started coverage on shares of Aardvark Therapeutics in a research report on Monday, March 10th. They set an "overweight" rating and a $29.00 target price for the company. Bank of America upped their price target on Aardvark Therapeutics from $22.00 to $26.00 and gave the company a "buy" rating in a research note on Thursday, March 27th. Finally, Royal Bank of Canada began coverage on shares of Aardvark Therapeutics in a report on Monday, March 10th. They set an "outperform" rating and a $21.00 target price for the company.

Aardvark Therapeutics Price Performance

NASDAQ AARD traded down $0.53 on Tuesday, reaching $8.16. The company's stock had a trading volume of 208,458 shares, compared to its average volume of 146,422. Aardvark Therapeutics has a 52 week low of $6.79 and a 52 week high of $19.58.

Insider Activity

In other news, CFO Nelson Sun purchased 10,000 shares of Aardvark Therapeutics stock in a transaction on Friday, February 14th. The stock was purchased at an average price of $16.00 per share, with a total value of $160,000.00. Following the transaction, the chief financial officer now directly owns 99,484 shares in the company, valued at $1,591,744. The trade was a 11.18 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Tien-Li Lee bought 16,542 shares of the firm's stock in a transaction that occurred on Friday, February 14th. The stock was acquired at an average cost of $16.00 per share, with a total value of $264,672.00. Following the transaction, the chief executive officer now owns 1,496,175 shares of the company's stock, valued at $23,938,800. This represents a 1.12 % increase in their position. The disclosure for this purchase can be found here.

Remove Ads

About Aardvark Therapeutics

We are a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. We target biological pathways associated with alleviating hunger that we believe have the potential to deliver transformative outcomes for patients.